The efficacy of ICIs in NSCLC has been shown in various clinical trials, and PD-L1 immunohistochemistry (IHC) has been widely accepted as a predictive biomarker because of its association with increased efficacy of ICIs [7, 8]. Here, CD274 is linked to non-small cell lung carcinoma.